Creating a free account will enable you to subscribe to our daily and weekly email newsletters, as well as customize your reading experience to show only the categories most relevant to you.
Signing up only take a few minutes, so why not give it a try and see what you've been missing out on.
A new targeted therapy for asbestos-related tumours has shown promise in an animal model. The results, reported in the open access journal BMC Cancer, raise hopes of a new therapy for this currently incurable cancer.
Malignant mesothelioma (MMs) is a rare form of cancer, most commonly caused by exposure to asbestos. It tends to be diagnosed decades after exposure occurs, so is rarely caught early. Current treatments, including surgery and chemotherapy, have limited efficacy and unpleasant side effects.
Traditional chemotherapeutic drugs work by destroying cells that divide quickly. As such, they're indiscriminate killers, destroying healthy dividing cells such as those in the bone marrow, digestive tract and hair follicles, as well as cancer cells. The result is an unwelcome mix of side-effects including a weakened immune system, gastrointestinal problems and hair loss. Targeted therapies, which are designed to kill cancer cells and leave healthy tissue unharmed, are highly sought after.
The new targeted therapy is a silica microparticle, coated in antibodies that recognise a protein produced by the tumour cells in large amounts. When the microparticles are injected into a mouse model of the cancer, the antibody helps the microparticles bind to the tumour cells, where they are then able to release their hidden inner cargo - the chemotherapy drug doxorubicin.
The new therapy is more effective and less toxic than doxorubicin alone, Brooke T. Mossman and colleagues report. Tumours shrank, the cancer cells proliferated less, and the animals were able more or less to maintain their weight and health throughout the treatment. Overall, the data suggest that targeted therapy may prove better than chemotherapy alone.
Using this targeting approach, the authors were able to reduce the dose of doxorubicin used four-fold thus almost eliminating side effects and toxicity. And because the treatment appears to reduce the number of proliferating tumour cells, it may prove useful early on, when pre-malignant or malignant MM cells are first observed, but before disease has been confirmed by histology.
Authors: Sherrill L Macura, Jeremy L Steinbacher, Maximilian B MacPherson, Melissa J Lathrop, Mutlay Sayan, Jedd M Hillegass, Stacie L Beuschel, Timothy N Perkins, Page C Spiess, Albert van der Vliet, Kelly J Butnor, Arti Shukla, Marilyn Wadsworth, Christopher C Landry and Brooke T Mossman
Article adapted by Medical News Today from original press release. Click 'references' tab above for source.
Visit our Asbestos / Mesothelioma category page for the latest news on this subject.
Please use one of the following formats to cite this article in your essay, paper or report:
Central, BioMed. "A targeted approach to asbestos-related cancer." Medical News Today. MediLexicon, Intl., 11 Sep. 2013. Web.
5 Dec. 2013. <http://www.medicalnewstoday.com/releases/265907>
Central, B. (2013, September 11). "A targeted approach to asbestos-related cancer." Medical News Today. Retrieved from
Please note: If no author information is provided, the source is cited instead.
If you write about specific medications, operations, or procedures please do not name healthcare professionals by name.
For any corrections of factual information, or to contact the our editorial team, please use our feedback form. Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.
This page was printed from: http://www.medicalnewstoday.com/releases/265907.php
Visit www.medicalnewstoday.com for medical news and health news headlines posted throughout the day, every day.
© 2004-2013 All rights reserved. MNT (logo) is the registered trade mark of MediLexicon International Limited.